Collection of Blood Samples for In-Vitro Studies from Healthy Adult Blood Donors Who Have Received Oral Typhoid Vaccine (TY21A)

Who is this study for? Adult patients Typhoid Fever
What treatments are being studied? Vivotif Typhoid Vaccine
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

This is an open-label, non-randomized study. Volunteers will be vaccinated with the typhoid oral vaccine, Vivotif. Vivotif has been licensed by the Food and Drug Administration (FDA) for travelers to developing countries. Volunteers will also be asked to provide blood, saliva, and stool specimens over a follow-up time period of up to eight years. The specimens obtained in this clinical research study will be used to further the investigator's understanding of the protective immunological mechanisms that can be elicited systemically and may be applicable to other enteric pathogens.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• Age 18 years and older

• Good general health as determined by a screening evaluation within 28 days before blood donation

• Informed, written consent

Locations
United States
Maryland
University of Maryland, Baltimore, Center for Vaccine Development and Global Health
RECRUITING
Baltimore
Contact Information
Primary
Susan Holian, RN
susan.holian@som.umaryland.edu
410-706-6156
Time Frame
Start Date: 2004-01-16
Estimated Completion Date: 2030-06-30
Participants
Target number of participants: 150
Treatments
Experimental: Vaccination with Oral Typhoid Vaccine (Vivotif)
Volunteers receive immunization with Vivotif oral typhoid vaccine. Blood, saliva, and stool specimens are collected at subsequent visits.
Related Therapeutic Areas
Sponsors
Leads: University of Maryland, Baltimore

This content was sourced from clinicaltrials.gov

Similar Clinical Trials